Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Accumulated Expenses (2016 - 2020)

Historic Accumulated Expenses for Medifast (MED) over the last 7 years, with Q4 2020 value amounting to $22.6 million.

  • Medifast's Accumulated Expenses rose 7137.87% to $22.6 million in Q4 2020 from the same period last year, while for Dec 2020 it was $22.6 million, marking a year-over-year increase of 7137.87%. This contributed to the annual value of $22.6 million for FY2020, which is 7137.87% up from last year.
  • Per Medifast's latest filing, its Accumulated Expenses stood at $22.6 million for Q4 2020, which was up 7137.87% from $13.2 million recorded in Q4 2019.
  • In the past 5 years, Medifast's Accumulated Expenses ranged from a high of $22.6 million in Q4 2020 and a low of $301000.0 during Q3 2016
  • For the 5-year period, Medifast's Accumulated Expenses averaged around $9.9 million, with its median value being $9.2 million (2017).
  • In the last 5 years, Medifast's Accumulated Expenses surged by 32134.63% in 2016 and then skyrocketed by 2409.19% in 2019.
  • Over the past 5 years, Medifast's Accumulated Expenses (Quarter) stood at $4.8 million in 2016, then soared by 62.01% to $7.7 million in 2017, then surged by 37.87% to $10.6 million in 2018, then grew by 24.09% to $13.2 million in 2019, then soared by 71.38% to $22.6 million in 2020.
  • Its Accumulated Expenses stands at $22.6 million for Q4 2020, versus $13.2 million for Q4 2019 and $10.6 million for Q4 2018.